Fisetin for Cellular Senescence Reduction
Fisetin is among the most promising senolytics in animal work, but human trials are still underway.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- Not established; pilot human trials used 20 mg/kg/day (about 1400 mg) on 2 consecutive days per month, with results still pending
- Expected timeframe
- Not established
Protocol
- form
- Not applicable
- duration
- Not applicable
- co factor
- Evidence is insufficient, though this is the most credible fisetin claim. Fisetin is the strongest senolytic among a screen of flavonoids in mouse studies, selectively clearing senescent cells and extending median and maximum lifespan in aged mice even when started late in life. Human trials at the Mayo Clinic and elsewhere use an intermittent hit-and-run schedule of roughly 20 mg/kg/day for two consecutive days each month, in frailty, osteoarthritis, chronic kidney disease and post-COVID studies. Most have not reported results, and no completed randomised trial demonstrates senescent cell clearance or clinical benefit in humans. The rationale is genuinely interesting; the human evidence does not yet exist.
- titration
- Not applicable
- starting dose
- Not applicable as an established treatment
Evidence
What the studies say
Fisetin is a senotherapeutic that extends health and lifespan
Yousefzadeh MJ, Zhu Y, McGowan SJ +19 more
Fisetin was the most potent senolytic of the flavonoids tested and extended median and maximum lifespan in aged mice.
Senolytic drugs: from discovery to translation
Kirkland JL, Tchkonia T
The first senolytic drugs Dasatinib, Quercetin, Fisetin and Navitoclax were discovered using a hypothesis-driven approach.
Safety
Caveats
This is experimental. Fisetin has no established safe long-term dose in humans, no upper intake level, and no safety data in pregnancy or breastfeeding - avoid in both, and in children. The intermittent monthly schedule used in trials exists because chronic dosing safety is unknown, so daily high-dose self-administration goes beyond anything studied. Senolytics by design kill cells, and off-target effects on healthy cells, wound healing and immune function are not characterised in humans. Fisetin inhibits cytochrome P450 enzymes and P-glycoprotein in vitro, making interactions with anticoagulants, chemotherapy, immunosuppressants and narrow-therapeutic-index drugs plausible but unquantified. It has antiplatelet activity in vitro - stop before surgery. Anyone with cancer, chronic kidney disease or on immunosuppression should not self-administer; join a trial instead.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.